Transforming drug delivery for women
Callavid® is at clinical-stage for fertility and pregnancy, with future applications in menopause, cancer, infectious diseases, and delivery of live biotherapeutics.
— As featured in —
Current methods of vaginal drug delivery are profoundly inadequate for millions of women around the world
Learn more about the current state of vaginal drug delivery
Our patented Callavid® platform technology inspires dosage confidence with greater user convenience
Learn more about the Callavid® technology and how it can improve drug delivery and patient experiences
“Callavid will be unbelievably popular with miscarriage patients as pessary leakage is the most frequent complaint, causing significant anxiety. The benefits of reducing psychological trauma, anxiety and depression are badly needed.”
Professor Siobhan Quenby
Director Biomedical Research Unit in Reproductive Health,Professor of Obstetrics University of Warwick,
Deputy Director Tommy’s National Centre for Miscarriage Research,
Calla Lily Clinical Care Medical Advisor
The vagina’s huge medical potential has gone untapped, but not for much longer
“Calla Lily has developed a new leak-free vaginal drug delivery platform. It's simple to use (essential when patients have to administer medications themselves) and also helps to alleviate dosage anxiety and other stresses”
“Thanks to NICE’s new miscarriage management guidance, for the first time we now have a recommended medication to prescribe to help reduce the incidence of miscarriages: vaginal micronised progesterone. This new device addresses patients’ issues of leakage and inconvenience previously associated with vaginally-delivered progesterone.”
Dr Stuart Lavery
Divisional Clinical Director of Women’s Health at UCLH,Calla Lily Clinical Care Medical Advisor
“This novel platform is of great benefit to anyone using a vaginally-delivered medication. By addressing the major issue of leakage, women can be assured the device delivers the correct dose in a convenient, tidy and less invasive fashion. It is truly a transformative device.”
Dr Kelle Moley
Former Deputy Director of Reproductive Health Technologiesat the Bill & Melinda Gates Foundation,
Calla Lily Clinical Care Medical Advisor